About Waylivra
About Waylivra
Waylivra is the only therapy licensed to treat FCS as an adjunct to diet in adult patients, in whom diet and triglyceride lowering therapy has been inadequate1
Waylivra inhibits formation of ApoC-III1
In FCS, inherited LPL dysfunction prevents the metabolism of triglycerides (carried by chylomicrons) through the LPL-dependent pathway.2
- Waylivra is an antisense oligonucleotide that inhibits the production of apoC-III by binding to its mRNA and preventing its translation.1
- By reducing apoC-III, Waylivra removes an inhibitor of triglyceride clearance, enabling triglyceride metabolism through an LPL-independent pathway in patients with FCS.1
References
- Waylivra® SmPC
- Gaudet D, et al. N Engl J Med. 2014;371:2200–2206